MHRA Approves First Targeted Drug for SOD1-ALS
The approval makes tofersen the first targeted therapy in the UK against this rare form of motor neurone disease (MND) with a genetic basis.
A Rare but Aggressive Condition
SOD1-ALS causes the body to produce a misfolded, toxic version of the SOD1 protein. This triggers motor neuron degeneration in the brain and spinal cord.
Patients experience progressive muscle weakness, atrophy, respiratory decline, and eventual paralysis and death.
SOD1 mutations are responsible for approximately 2% of all ALS cases globally. Over 200 distinct mutations in SOD1 have been identified, each contributing to a wide range of disease progression rates. This variability highlights the importance of developing targeted therapies for SOD1-ALS.
How Tofersen Works
Tofersen is an antisense oligonucleotide that binds to SOD1 mRNA, promoting its degradation through an RNase H-mediated mechanism. This reduces the production of the toxic SOD1 protein.
The drug is administered via intrathecal injection through a lumbar puncture at scheduled intervals, under the supervision of trained healthcare professionals.
Success in Clinical Trials
The approval was supported by data from the phase 3 VALOR study and its open-label extension (OLE).
In the VALOR trial, 108 adults with SOD1-ALS were treated with either intrathecal tofersen (n=72) or placebo (n=36) for 28 weeks.
The primary endpoint, the ALSFRS-R score — which assesses bulbar, motor, and respiratory functions — showed a positive trend with tofersen, although the difference was not significant. However, tofersen significantly reduced biomarkers of neurodegeneration, including cerebrospinal fluid (CSF) SOD1 protein levels and plasma neurofilament light chain (NfL) concentrations. By week 28, plasma NfL levels decreased by 55% in the tofersen group, compared to a 12% increase with placebo.
Clinical trends suggested improvements in respiratory function, muscle strength, and quality of life. These effects were more pronounced with earlier treatment and during the OLE phase.
Safety and Tolerability
The most common side effects in tofersen-treated patients included:
Back, muscle, and joint pain
Fatigue
Fever
Raised CSF protein levels or white blood cell counts
These reactions were generally mild to moderate in severity.
Further information, including the Patient Information Leaflet and Summary of Product Characteristics, will be available on the MHRA website within 7 days of approval.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
3 Healthcare Stocks Paying the Highest Dividends of 2025
Key Points SIGA Technologies has a sky-high dividend yield that comes with a catch. Pfizer's dividend remains strong despite a looming patent cliff. Spok Holdings offers an attractive dividend and outstanding growth. 10 stocks we like better than Pfizer › The healthcare sector has long been a favorite for income investors -- and for good reason. Many healthcare stocks offer attractive dividend yields. Some stocks stand out more than others, though. Here are the three healthcare stocks paying the highest dividends in 2025. 1. SIGA Technologies SIGA Technologies (NASDAQ: SIGA) focuses primarily on developing drugs for treating orthopoxviruses. Its flagship product is TPOXX, an antiviral medication that's approved in the U.S. and Canada for treating smallpox and in Europe, Japan, and the U.K. for treating smallpox, mpox, cowpox, and vaccinia complications. The company's dividend yield is a lofty 9.29%. However, there's something investors should know about SIGA's dividend. The drugmaker doesn't pay a regular dividend but, instead, has declared special cash dividends for four consecutive years. Special cash dividends usually aren't viewed as favorably by income investors as established programs that pay dividends on a monthly or quarterly basis. The risk that a company will decide against paying a special cash dividend in the future is probably higher than the risk that a company will suspend a regular dividend. SIGA's ability to pay dividends in the future depends largely on how seriously governments perceive the threat posed by smallpox, mpox, and other orthopoxviruses. For now, the threat level is high. That probably bodes well for the company declaring a special cash dividend in 2026, but it's difficult to predict what will happen with SIGA's dividend beyond then. 2. Pfizer Pfizer (NYSE: PFE) is the most well-known of the high-paying healthcare dividend stocks on this list. The company was founded in 1849. Today, it's one of the biggest drugmakers on the planet, with a market cap of over $130 billion and a lineup that includes multiple blockbuster drugs. Income investors have a lot to like about Pfizer. Its forward dividend yield stands at 7.32%. The company has paid a dividend for 346 consecutive quarters and has increased its dividend for 16 consecutive years. Its management team remains committed to sustaining and growing the dividend. Pfizer faces some challenges that could limit how much it's able to increase the dividend over the next few years, though. By the end of 2028, the company will lose patent protection for kidney cancer drug Inlyta, autoimmune disease drug Xeljanz, blood thinner Eliquis, breast cancer drug Ibrance, prostate cancer drug Xtandi, rare-disease franchise Vyndaqel/Vyndamx, and Mektovi, which treats melanoma and non-small cell lung cancer. While this patent cliff admittedly looks daunting, Pfizer's dividend shouldn't be in danger. The drugmaker has several rising stars, including migraine therapy Nurtec ODT and cancer drugs Padcev, Lorbrena, and Elrexfio. Pfizer's pipeline is also loaded with promising candidates, including 30 late-stage programs. 3. Spok Holdings Spok Holdings (NASDAQ: SPOK) specializes in healthcare communication and collaboration solutions. The company's flagship product, Spok Care Connect, is a unified communication platform that provides closed-loop communication, secure messaging, and collaboration capabilities to clinical teams. While Spok mainly focuses on hospitals, it also sells products to large government agencies, public-safety institutions, academic institutions, and other commercial customers. There's good news and bad news with Spok's dividend. First, the bad news: Don't expect dividend increases. Spok hasn't increased its dividend since 2022. The good news, though, is that the dividend is attractive, with a forward yield of 6.75%. Want more good news? Spok's business is booming. The company's earnings jumped 33% year over year in the second quarter of 2025. Its software operations bookings were 34% higher than the prior-year period. Unsurprisingly, Spok's stock has also performed well and is handily beating the market so far this year. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. 3 Healthcare Stocks Paying the Highest Dividends of 2025 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
an hour ago
- Medscape
Neoadjuvant vs Adjuvant Immunotherapy in Colon Cancer
The results of the phase III ATOMIC trial fired another volley in the ongoing debate over adjuvant vs neoadjuvant immunotherapy for patients with locally advanced colon cancer. But experts are divided about which treatment plan is the best. Adjuvant immunotherapy plus chemotherapy has yet to square off against neoadjuvant immunotherapy in a head-to-head trial. Even if that trial doesn't happen, post hoc analyses of ATOMIC and the neoadjuvant NICHE-2 studies may clarify whether a one-size-fits-all approach is appropriate and help determine which patients benefit more from one approach over the other, according to Christopher Lieu, MD, an investigator in the ATOMIC study. The ATOMIC study showed that adding adjuvant immunotherapy to standard-of-care chemotherapy following resection reduced the risk for disease recurrence or death by 50% compared with chemotherapy alone in the 355 patients with stage III colon cancer with mismatch repair deficiency (dMMR), who received adjuvant atezolizumab along with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy, providing those in the pro-adjuvant camp with important data. In addition, 3-year disease-free survival (DFS) was 86.4% with the combination compared with 76.6% with chemotherapy alone. The results of this trial were presented at the American Society of Clinical Oncology (ASCO) 2025. 'These data established this combination as a new standard treatment for patients with stage III colon cancer and deficient mismatch repair,' said study author Frank A. Sinicrope, MD, during a press conference at the meeting. 'We regard this as a highly impactful study that will change clinical practice, and it actually represents the first immunotherapy adjuvant study in colon cancer.' In NICHE-2, patients were given neoadjuvant ipilimumab or nivolumab followed by surgical resection. At 3 years, 100% of all 111 patients treated with ipilimumab and nivolumab prior to surgery were recurrence-free, according to a presentation at last year's annual meeting of the European Society for Medical Oncology (ESMO). The DFS beat the prespecified success threshold of 93%. Adding Immunotherapy The standard treatment for stage III colon cancer, regardless of dMMR status, is surgical resection followed by FOLFOX chemotherapy. However, about 15% of patients with stage III colon cancer have dMMR and display resistance to chemotherapy, providing a rationale for adding immunotherapies to standard treatment. 'These tumors are unable to repair their DNA and therefore accumulate mutations that trigger an immune response that is ineffective due to immune checkpoint proteins. Therefore, the use of immune checkpoint inhibitors is very attractive in this setting,' Sinicrope said during the press briefing. Sinicrope is professor of medicine and oncology, and coleader of the Gastrointestinal Cancer Program at Mayo Clinic in Rochester, Minnesota. Adjuvant Immunotherapy The ATOMIC trial is significant because it demonstrates improved DFS with the addition of immunotherapy to standard chemotherapy treatment, improving outcomes for patients with this type of locally advanced cancer over standard care. There are several rationales for adding immunotherapy following surgical resection. For example, staging relies on tumor appearance on CT scan, said Lieu, who is the codirector of Gastrointestinal Medical Oncology at the University of Colorado Cancer Center in Aurora, Colorado. There are patients with dMMR or microsatellite instability-high (MSI-H) colon cancer that appear to have stage I or II disease on their CT scan. 'In those patients, starting with immunotherapy first may not be the best idea because after a stage I or II colon cancer is resected, they don't require any further therapy because of the low risk of recurrence,' he said. 'If you think it is an early-stage cancer based of radiographic findings, you could cut out the cancer and then only offer chemotherapy and immunotherapy if it is unexpectedly stage III. I think that there's certainly rationale for that,' he continued. Other arguments for adjuvant immune checkpoint inhibitors, like atezolizumab, with chemotherapy include synergy between cytotoxic and immune mechanisms and systemic insurance against micrometastatic spread. It also avoids the potential for rare immune complications from upfront immunotherapy that could delay surgery. 'I don't think that [giving all patients neoadjuvant treatment] is the answer. If you think that they have stage I or stage II colon cancer at the beginning, then you might end up hurting them with upfront immunotherapy,' said Lieu. Neoadjuvant Immunotherapy The standard treatment for stage III colon cancer, regardless of dMMR status, is surgical resection followed by chemotherapy, FOLFOX and capecitabine and oxaliplatin (CAPOX) are two of the most common regimens. However, chemotherapy can be hard on patients, making neoadjuvant immunotherapy that can reduce or eliminate the need for post-surgical chemotherapy very attractive. The data from the NICHE-2 trial support the efficacy of neoadjuvant immunotherapy. 'The data strongly suggest that neoadjuvant immunotherapy is better than adjuvant immunotherapy and that chemotherapy for dMMR colorectal cancer has limited activity,' said Michael J. Overman, MD, Associate Vice President of Research for the MD Anderson Cancer Network in Houston, in an interview. 'Thus, I am a believer that neoadjuvant is the preferred approach for dMMR localized cancers.' Lieu said neoadjuvant immunotherapy might be more appropriate for more aggressive disease. 'What we discuss in our multidisciplinary clinic is that if these patients are diagnosed prior to surgery and particularly if they have aggressive features…those are some of the patients that I really would consider for neoadjuvant therapy,' he said. 'While it's high-risk disease, there could be some benefit to down-staging the patient, so that there isn't a positive margin. If there's pathologic complete response…and you don't have to give adjuvant chemotherapy, most people would consider that to be a win.' Overman noted that 'a big open area relates to whether the goal of neoadjuvant therapy should be operation or no operation. Likely both approaches can be done and that would be up to patient and physician.' However, 'with a nonoperative approach, we still have unknowns regarding disease assessment and surveillance for neoadjuvant therapy.' Patient-Specific Care In the absence of data from a head-to-head trial of the two approaches, a patient-specific approach may be the appropriate strategy, Lieu suggested. 'If I had a take home message, it's just that it's clear that these patients really require multidisciplinary discussion before an operation,' he said. Molecular testing has an important role to play as well, said Lieu. 'It speaks to the importance of doing biomarker testing for MMR, MSI, or both. Alarm bells should be ringing as soon as [either or both come] back positive; it should make everyone think for a second and make sure we have the right plan for the right patients.' Sinicrope reported several relationships, including with Eli Lilly, Guardant Health, Roche Holdings AG, Ventana Medical Systems, and Woven Health Collective. Lieu reported relationships with Amgen and Genentech.
Associated Press
an hour ago
- Associated Press
Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress
Wuppertal, Germany, August 5, 2025 - Aicuris Anti-infective Cures AG today announced initial clinical data from its ongoing first-in-human Phase 1 trial with AIC468. The novel antiviral antisense oligonucleotide is in development for the treatment of BK virus (BKV) infections in kidney transplant recipients. The interim results, presented at the World Transplant Congress in San Francisco on August 4, 2025, provide an overview of PK characteristics of AIC468 from the Phase 1 clinical trial in healthy volunteers. 'BK virus infections represent a serious and persistent threat for immunocompromised patients with a high risk of renal damage or kidney loss after transplantation. The PK results and safety data to date are very encouraging and provide us with valuable insights for the continued development of this differentiated program,' said Cynthia Wat, MD, CMO of Aicuris. 'Our goal is to achieve tangible therapeutic solutions for immunocompromised patients with kidney transplants, and these strong PK and safety data are an important step for us in achieving this goal.' FIH trial data from 72 healthy volunteer subjects, six single ascending dose (SAD) subcutaneous cohorts, one intravenous dose level and two multiple ascending dose (MAD) subcutaneous cohorts were presented at World Transplant Congress. AIC468 was safe and well tolerated across all cohorts investigated to date. The product candidate achieved excellent bioavailability (82%), rapid absorption, and distribution to peripheral tissues. A favorable half-life together with pre-clinical data, suggests that efficacious kidney concentrations can be attained by weekly or less frequent dosing regimens within the investigated dose range. Additionally, renal clearance for AIC468 accounted for less than 2% of the total clearance, representing a negligible route of elimination. Tissue uptake and subsequent metabolism appear to be the primary route of clearance, supporting the observed benign safety profile. The trial is progressing as planned in the third MAD cohort. 'Aicuris continues to build momentum by executing on our clinical trial strategy and achieving the first positive data set for our third clinical program for immunocompromised patients,' added Larry Edwards, CEO of Aicuris. 'In the second half of 2025 we expect data from the Phase 1 program to allow us to rapidly advance AIC468 into a Phase 2a proof-of-mechanism trial in H1 2026 to demonstrate its value for patients.' The randomized, double-blind, placebo-controlled first-in-human trial ( 2023-510074-13-00 ) is designed to evaluate the safety, tolerability and pharmacokinetics of AIC468 in healthy volunteers. SAD cohorts tested AIC468 or a placebo control in a total of 56 healthy volunteers across six subcutaneous (25 mg to 600 mg) and one intravenous dose level (200 mg). In the MAD cohorts an additional 24 subjects receive five repeated doses of AIC468 (130 mg, 230mg and 330 mg). Dosing in all SAD and the first two MAD cohorts have been successfully completed. The trial is progressing as planned in the third MAD cohort with data expected later this year. About BKV BKV is a ubiquitous polyomavirus that infects most people in early childhood, typically without symptoms. In immunocompromised individuals, such as organ transplant recipients, BKV can reactivate, leading to serious health issues. In kidney transplant patients, BKV reactivation can cause BK virus-associated nephropathy (BKVAN), affecting up to 10% of recipients and potentially resulting in graft loss. Current management involves reducing immunosuppressive therapy, which increases the risk of graft rejection. Despite its prevalence, there is no approved antiviral treatment specifically for BKV. About AIC468 AIC468 is an antisense oligonucleotide therapy designed to treat BK virus reactivation in kidney transplant patients which can pose a significant health risk for these patients. The candidate blocks viral replication within infected cells by inhibiting splicing of the pre-mRNA that encodes for the virus' large T-antigen. This innovative approach has already demonstrated potent antiviral activity along with a favorable pharmacokinetic and safety profile in preclinical studies and is currently being evaluated in a Phase 1 clinical trial. About Aicuris Aicuris is meeting the needs of the growing population of immunocompromised people who require precise therapies to effectively treat infection. Our flagship product, PREVYMIS®, marketed by our partner MSD, prevents CMV in a defined group of transplant recipients. Our pivotal Phase 3 candidate, pritelivir, aims to address refractory HSV infections in a broad population of patients with weakened immune systems. For immunocompromised people, an otherwise manageable infection can mean life or death. Aicuris, with its expertise and growing pipeline, is committed to providing therapeutic solutions for them now and in the future. Contact: Aicuris Anti-infective Cures AG [email protected] Trophic Communications Dr. Stephanie May and Dr. Charlotte Spitz Phone: +49 171 3512733 Email: [email protected]
